LC
EVOK

Lindbrook Capital’s Evoke Pharma EVOK Stock Holding History

Lindbrook Capital’s Portfolio EVOK Stock Details EVOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-7
Closed -$158 – 2763
2023
Q1 		$158 Hold
7
– – ﹤0.01% 2730
2022
Q4 		$222 Hold
7
– – ﹤0.01% 2715
2022
Q3 		$0 Hold
7
– – ﹤0.01% 2703
2022
Q2 		$0 Hold
7
– – ﹤0.01% 2561
2022
Q1 		$0 Hold
7
– – ﹤0.01% 2514
2021
Q4 		$1K Hold
7
– – ﹤0.01% 1911
2021
Q3 		$1K Hold
7
– – ﹤0.01% 1708
2021
Q2 		$1K Hold
7
– – ﹤0.01% 1750
2021
Q1 		$2K Hold
7
– – ﹤0.01% 1536
2020
Q4 		$3K Hold
7
– – ﹤0.01% 1330
2020
Q3 		$5K Hold
7
– – ﹤0.01% 1104
2020
Q2 		$4K Hold
7
– – ﹤0.01% 1150
2020
Q1 		$1K Hold
7
– – ﹤0.01% 1439
2019
Q4 		$2K Hold
7
– – ﹤0.01% 1279
2019
Q3 		$1K Hold
7
– – ﹤0.01% 1350
2019
Q2 		$0 Hold
7
– – ﹤0.01% 1429
2019
Q1 		$1K Hold
7
– – ﹤0.01% 1298
2018
Q4 		$2K Buy
+7
New +$2.59K ﹤0.01% 1166

Other funds holding EVOK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
CWP
Concord Wealth Partners Abingdon, Virginia $873M AUM 24.02% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Lindbrook Capital's EVOK Position: Q2 2023 in Review

Lindbrook Capital sold out of Evoke Pharma (EVOK) in Q2 2023, closing a stake of 7 shares — an estimated $158 sold.

Lindbrook Capital first reported a position in EVOK in Q4 2018 and held it in 18 quarters. The position peaked at $5K in Q3 2020. 10 funds tracked by Wall St. Rank hold EVOK as of Q2 2023.

  • Lindbrook Capital reported no remaining Evoke Pharma position as of Q2 2023 after selling out during the quarter.
  • Lindbrook Capital sold 7 Evoke Pharma shares in Q2 2023, an estimated $158.
  • Lindbrook Capital first reported a position in Evoke Pharma in Q4 2018 and held it in 18 quarters.
  • Lindbrook Capital's Evoke Pharma position peaked at $5K in Q3 2020.
  • 10 funds tracked by Wall St. Rank held Evoke Pharma as of Q2 2023.

Based on Lindbrook Capital's 13F filing for Q2 2023, filed 31 Jul 2023.